Weight Loss Drug Meridia Recalled From Market

Abbott Laboratories has been less drug Sibutramine (Reductil) from the market because of increased risk of cardiovascular disease. Weight loss drug Reductil (Meridia) has been eliminated in the U.S. market by its manufacturer, Abbott Laboratories. The company's decision comes as a result the request of the Food and Drug Administration (FDA) authority. The FDA reviewed the results of Abbott Laboratories clinical trial, Reductil, Sibutramine Cardiovascular Study Results (SCOUT), and found that the drug posed a significant risk of an event vaskulaarihaitoille patients. This study was a large double-blind study done in Europe, Latin America and Australia and involved 10 000 overweight / obese people with a history of cardiovascular events. SCOUT results found that patients takng the drug was 16% higher risk of experiencing adverse cardiovascular events such as nonfatal myocardial infarction. non-fatal stroke or resusciation after cardiac arrest. Patients taking the drug, the study found that over five years, only a small weight loss occurred in patients compared with placebo. Sibutramine was approved by the FDA for use in obese patients, classified as patients with a BMI over 30 kg/m2 and in addition to patients with a BMI 27 kg/m2, which are caridovascular risks. The intention is that the medicine is used in combination with low-calorie diet. The press release, Abbott Laboratories, said that SCOUT results are exceptional, and 46 controlled clinical trials of sibutramine and over 6 million years for the patient's history throughout its 13 years the market has not shown the same results into a heart drug. The company believes that the risk / benefit levels for drugs are positive and that it should be allowed on the market. At this stage, withdrawal of drug influence in Europe and the U.S. market only. The FDA recommends that patients currently taking Reductil (Meridia) should stop the drug and discuss your options and their health care professionals.